^
    8d
    First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. (PubMed, ESMO Open)
    PADMA is the first randomized multicenter study to show that palbociclib + ET as first-line treatment compared with CT also leads to improvements in TTF and PFS in predominantly postmenopausal patients with HR-positive/HER2-negative mBC.
    Clinical • P4 data • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation
    |
    Ibrance (palbociclib) • paclitaxel • capecitabine • epirubicin • vinorelbine tartrate
    10d
    Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization. (PubMed, Curr Cancer Drug Targets)
    Six prognostic genes, particularly RAB25 and PLAU, influence ESCC progression and immune microenvironment remodeling.
    Journal
    |
    SERPINH1 (Serpin family H member 1) • MAGEA4 (Melanoma antigen family A, 4) • ANO1 (Anoctamin 1) • COL2A1 (Collagen Type II Alpha 1 Chain) • PLAU (Plasminogen Activator) • RAB25 (RAB25, Member RAS Oncogene Family)
    |
    cisplatin • docetaxel • vinorelbine tartrate
    22d
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    24d
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • BNT326
    28d
    The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study. (PubMed, Transl Breast Cancer Res)
    Treatment interruption, modification, or discontinuation due to treatment-related AEs was uncommon (12.1%). Metronomic vinorelbine plus anlotinib shows favorable efficacy in HER2- advanced breast cancer without increasing the risk of AEs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • vinorelbine tartrate
    1m
    Histology-Based Induction Chemoradiotherapy Followed by Surgery for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Prospective Observational Study. (PubMed, Ann Thorac Cardiovasc Surg)
    Histology-based induction CRT followed by surgery demonstrated feasibility and favorable outcomes, particularly for Sq and EGFR-negative non-Sq NSCLC. These findings provide a reference for patients ineligible for immune checkpoint inhibitor-based therapy.
    Observational data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR negative
    |
    cisplatin • pemetrexed • vinorelbine tartrate
    1m
    Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer (clinicaltrials.gov)
    P=N/A, N=45, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • vinorelbine tartrate
    1m
    Orbital alveolar rhabdomyosarcoma with central nervous system invasion in adult: A case report. (PubMed, Surg Neurol Int)
    The patient received adjuvant radiotherapy and chemotherapy with irinotecan, vincristine, actinomycin D, ifosfamide, cyclophosphamide, and vinorelbine. The lack of guidelines for the adult population implies the need to adapt therapeutic strategies from pediatric protocols. Comprehensive diagnosis integrating imaging, histopathology, and molecular testing is essential for accurate classification and treatment planning.
    Journal
    |
    PAX3 (Paired Box 3)
    |
    cyclophosphamide • ifosfamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin
    1m
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=30, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026
    Trial completion • Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate
    1m
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc.
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • eribulin mesylate • vinorelbine tartrate • evorpacept (ALX148)
    1m
    OptiTROP Breast02: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • eribulin mesylate • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    1m
    ALINA: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=257, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2031
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate